WILBUR BLECHMAN, M.D.; JOHN H. VAUGHAN, M.D.
Hench and his co-workers1 introduced cortisone as a therapeutic agent for the treatment of rheumatic diseases in 1949. Since then this hormone and related derivatives have been extensively used, and their clinical values and limitations have been more fully described.
Although the mechanism of corticosteroid antiphlogistic effect has not been well defined, several observations give us hints as to possible pathways for this action. A general depressant effect of corticosteroids upon nitrogen metabolism can often be demonstrated as a negative nitrogen balance. Instances of suppressed cell function, such as the impaired ability of phagocytes to dispose of ingested particles,2 suppressed
BLECHMAN W, VAUGHAN JH. PROBLEMS IN THE CORTICOSTEROID THERAPY OF RHEUMATIC DISEASE(PROBLEMS IN THE CORTICOSTEROID THERAPY OF RHEUMATIC DISEASE*). Ann Intern Med. 1959;50:571–585. doi: 10.7326/0003-4819-50-3-571
Download citation file:
Published: Ann Intern Med. 1959;50(3):571-585.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use